{"name":"Eleison Pharmaceuticals","slug":"eleison","ticker":"ELSN","exchange":"OTC","domain":"eleisonpharm.com","description":"Eleison Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for dermatology and oncology conditions. The company's pipeline includes several promising candidates, including its lead product, ELSN-101, which has shown promising results in clinical trials. With a strong presence in the US market, Eleison Pharmaceuticals is well-positioned to capitalize on the growing demand for effective treatments in these therapeutic areas. The company's commitment to research and development has enabled it to establish a strong reputation in the industry.","hq":"Bedminster, NJ","founded":0,"employees":"","ceo":"David Carberry","sector":"Dermatology / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ELSN-101 patent cliff ($123.4M at risk)","drug":"ELSN-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"earnings","headline":"Eleison Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Eleison Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $45.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Eleison Pharmaceuticals Announces Collaboration with Leading Research Institution","summary":"Eleison Pharmaceuticals announced a collaboration with a leading research institution to develop new treatments for skin cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"regulatory","headline":"FDA Approves ELSN-101 for Treatment of Advanced Skin Cancer","summary":"The US FDA approved ELSN-101 for the treatment of advanced skin cancer, marking a significant milestone for Eleison Pharmaceuticals.","drugName":"ELSN-101","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNNUNQbWVZWFJ3d3NReTFtaWh5N1lCVHNDQlR4YUZvX1hkYW1iUmUwZm1MOVJ3V19ZWVRHS2ZDZXBSdExNbXFYYWJFQ1huVmZ1QkJtSFd1UDRaSng0LVJHbEJwbGFrRVhQWF9LNHptYTc4dld6MEZXZWlhVU1VN0pfNjBuS0tTN0hUSzJHX3pRNUZjTVcwYkxKakJRWS1Xc0JnWnRHdHliTHF6NFlBWVJ4WkZjZE9tX2RvbmpCZlVR?oc=5","date":"2023-06-29","type":"pipeline","source":"renaissancecapital.com","summary":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals withdraws $42 million IPO - renaissancecapital.com","headline":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals withdraws $42 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQTW1COWFoeGNIb3ZRUGhvaXVHRTQzdEFsN0pwUVQ5a0c5WnRSbm5yX3ZkbWdMendCTGZSZms5MmJDYnN2Vm5xd0IxOFJCbUQzeGxWaGpHYWtLME9EMFJYdUg4dEtpWGJIWnBTQzdqSjBOTUl6WW14Zm81QTE5aDhpWm54TE10eHY2V2YtYmNrQQ?oc=5","date":"2022-01-26","type":"pipeline","source":"SEC.gov","summary":"elph20220114_s1.htm - SEC.gov","headline":"elph20220114_s1.htm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOa0hQcFloMWkwb3hYMUYxaVdxNVNaUmNfd3E3eHVzU0VzUnNhTUczVTA0VkdBM1pENDA5Y2YzUGR6c0FNMnE5RFdfRDdtZVRRakRKM080aEV4OTJfVUp0dm9DUEJjYUxhZmRXclh6MGtQaXY5bVhhVTN1M3VrdTBxMXc4ejl5akU4eFRhWVY5V2ZBWHZlMHA5T3NQWTRLNHlYd2JSNGZaX0lMQmVnYUdEeUNMN3R6TjBQdGxwNEJ5VTU?oc=5","date":"2022-01-24","type":"pipeline","source":"renaissancecapital.com","summary":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals files for a $42 million IPO - renaissancecapital.com","headline":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals files for a $42 million IPO","sentiment":"neutral"}],"patents":[{"drugName":"ELSN-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":123400000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["Dermatology","Oncology"],"financials":null,"yahoo":null}